Experts Directory

The 2020 TissueTech Experts Directory is a reference tool designed for those seeking commentary on a wide variety of topics ranging from the treatment of ocular surface disease to the management of advanced wounds and traumatic injuries. Our experts are willing to provide quotes, add perspective to current news, or share their professional expertise on a wide array of topics.

To locate a TissueTech expert by topic, please scroll below and click open your selection. You can also find a topic or locate an expert by performing a keyword search. Or if you prefer, email TissueTech’s Public Relations Department and a member of our team will respond to your request within 24 hours.

TissueTech Experts


In the coming decades, people ≥ 65 years old will constitute the majority of diabetic patients in the United States and most other developed countries. It is estimated that 25 percent of people with diabetes will develop a foot ulcer in their lifetime.1  Today, scientists at TissueTech are conducting clinical research in the treatment of advanced wounds such as complex diabetic foot ulcers using cryopreserved umbilical cord derived from human birth tissue. We define advanced wound care therapies as interventions used when standard wound care has failed. A large and growing array of advanced wound care therapies of different composition and indications have been developed though their efficacy. Study results suggest that that cryopreserved umbilical cord is a promising therapy for the management of complex, nonhealing diabetic foot ulcers complicated by an infection in the bone.

 

Alan Block, DPM

  • Board Certified, American Board of Foot and Ankle Surgery
  • Doctor of Medicine, Kent State University College of Podiatric Medicine, Independence, OH
  • Residency, Circle City Hospital Corona, CA and Medical Center Hospital, Portland, OR

Dr. Block serves on the Editorial Board of the Journal of Vascular Surgery and on the Executive Council of the American Venous Forum and Society for Vascular Surgery. His research interests include the diagnosis and management of chronic venous insufficiency, the treatment of critical limb ischemia, and advanced therapies for healing chronic wounds. He has been a clinical investigator on over 50 clinical trials in the areas listed above, both on the local and national level. Dr. Block has experience in the design and conduct of clinical trials at all levels of the approval process.

 

William A. Marston, MD

  • Board Certified, Surgery and Surgery/Vascular Surgery
  • Doctor of Medicine, University of Virginia, Charlottesville, VA
  • Residency, University of North Carolina at Chapel Hill, Chapel Hill, NC
  • Fellowship in Vascular Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC

Dr. Marston’s research interests include the diagnosis and management of chronic venous insufficiency, the treatment of critical limb ischemia, and advanced therapies for healing chronic wounds. He has been a clinical investigator in over 50 clinical trials in the areas listed above, both on the local and national level and has experience in the design and conduct of clinical trials at all levels of the approval process. He currently serves on the Editorial Board of the Journal of Vascular Surgery and on the Executive Committee of the American Venous Forum and Executive Council of the Society for Vascular Surgery.

 

Jacob Wynes, DPM

  • Board Certified, Foot Surgery by the American Board of Foot and Ankle Surgery
  • Board Certified, Ankle Surgery by the American Board of Foot and Ankle Surgery
  • Doctor of Medicine, Temple University School of Podiatric Medicine, Temple University, Philadelphia, PA
  • Residency, Hospital of the University of Pennsylvania, Pennsylvania, PA
  • Fellowship in Foot and Ankle Deformity, Sinai Hospital of Baltimore, Baltimore, MD

Dr. Wynes currently manages foot and ankle care for children and adults at the University of Maryland Medical System. With his fellowship training in foot and ankle deformity correction, he is routinely called upon to provide advanced treatment options for congenital and progressive conditions including the treatment of advanced wounds. Dr. Wynes handles a vast array of issues, from the most basic bunion or hammertoe surgery to complex realignment and tendon transfers using human birth tissue allograft, ankle arthroscopy and metatarsal lengthening.

Scientific research is proving that the clinical use of human birth tissue can produce an abundance of growth factors that show promise as tissue scaffolds aiding in the regeneration of human bone and soft tissue. This restorative ability is innate in cryopreserved amniotic membrane and umbilical cord. Heavy chain hyaluronic acid/pentraxin-3 is the key protein complex present in these tissues to orchestrate the healing process. Today, scientists at TissueTech are finding that adjunctive use of cryopreserved umbilical cord is proving highly successful in treating orthopedic disorders and could improve clinical and functional outcomes as illustrated in a pilot study showing that after arthroscopic repair of talar osteochondral defect within the ankle joint, postoperative pain and inflammation, was reduced and recovery was accelerated. This research is very promising for orthopedic surgeons and their patients. Herbert Slade, MD, FAAAI, Medical Director at TissueTech is available for comment and to speak on advances in the application of cryopreserved umbilical cord and amniotic membrane to treat orthopedic injuries.

 

Herbert Slade, MD, FAAAI, Medical Director, TissueTech, Inc.

  • Board Certified in Pediatrics, Allergy & Immunology
  • Doctor of Medicine, S.U.N.Y. Upstate Medical University, Syracuse, NY
  • Bachelor of Arts, Hamilton College, Clinton, NY
  • 2018 – 2021, Treasurer and Member of the Board of Directors, Wound Healing Society
  • World Health Organization – representative to Global Program on AIDS
  • S. Health & Human Services Advisory Committee on Regulatory Reform – invited panelist

Dr. Slade is a dual board-certified subspecialist in pediatrics and clinical immunology with more than 25 years of industry-based experience in clinical research and drug development. After holding academic appointments at the University of Michigan and Cornell University Medical Center, he left academia in 1989 to work with Jonas Salk, MD, on an HIV therapeutic vaccine joint venture, taking the position of Director of AIDS and Immunology at Rhône-Poulenc Rorer (now Sanofi-Aventis).

Many biotechnology startups rely on funding from private investors. Leadership at TissueTech has successfully met the challenges that young biotech startups face in meeting investors’ expectations when moving from product development to commercialization and launch, as illustrated by the success of TissueTech co-founder Amy Tseng, MBA, President and Chief Executive Officer. All business and finance activities are conducted under Amy’s oversight. She is available to speak about trends in biotech venture capital funding and the outlook for venture investment.

Amy Tseng, MBA, President & Chief Executive Officer, Co-Founder, Board Member, TissueTech, Inc.

  • Bachelor of Science, National Taiwan University
  • Master of Business Administration, University of Southern California, Los Angeles, CA

Amy Tseng is the co-founder of TissueTech and is the Company’s President and Chief Executive Officer. Her vision for the organization is to commercialize human birth tissue derived products as platform technologies for regenerative medicine. Since the Company’s inception, Amy has presided over this vision by building the company into an industry leader and spearheading the company’s expansion into new fields of use in orthopedics, podiatry, wound care, ophthalmology, optometry, urology, trauma, oncology, non-opioid pain management, and obstetrics/gynecology surgical subspecialties, etc.. In June 2019, Amy oversaw the closing of an $82.25 million round of Preferred C equity financing led by EW Healthcare Partners (formerly Essex Woodlands) followed by the third round of continuous investments from Ballast Point Ventures. As of January 2020, Amy has raised $110 million in venture capital for TissueTech.

The U.S. Food and Drug Administration (FDA) protects the public’s health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices. In November 2017, the FDA issued new guidance to the human cell and tissue-based product (HCT/P) industry in efforts to ensure safer and more efficacious delivery of HCT/Ps to patients. As a result, TissueTech is undergoing a rigorous biologics license application process that includes a series of investigational new drug clinical trials to treat chronic wounds, musculoskeletal disorders, and restore ocular surface function. These trials are being conducted at multiple locations throughout the United States under the supervision of Tommy Lee, MSHS, Vice President of Clinical Operations. Tommy is available to speak about clinical trials, clinical operations, and good clinical practice and regulations.

 

Tommy D. Lee, MSHS, Vice President of Clinical Operations, TissueTech, Inc.

  • Certified Clinical Research Associate
  • Bachelor of Science, Animal Science/Biology, Abilene Christian University
  • Master of Science Health Sciences, Clinical Research Administration, The George Washington University School of Medicine

Tommy’s research experience spans 20 years across multiple therapeutic areas in all phases of clinical development and product types. These include pharmaceuticals, biologics, medical devices and human cell and tissue products (HCT/Ps). He has managed and overseen global clinical teams and trials, held multiple roles in Clinical Operations, completed post graduate training focused in Clinical Research through Tufts University in Clinical Pharmacology, Drug Development and Regulations, Leadership for Drug Development Teams and maintains certification as a clinical research professional through the Association of Clinical Research Professionals. As Vice President of Clinical Operations at TissueTech, Tommy provides strategic leadership and input into the development of the clinical trial protocols, timelines, and budgets for the company’s assets so that the clinical designs are implemented in the most optimal manner to achieve their objectives.

Trauma of the foot and ankle is a common problem with over 280,000 ankle sprains occurring from 2007 to 2011, according to the National Trauma Data Bank.2,3 These injuries predispose patients to developing post-traumatic osteoarthritis (OA). Post-traumatic OA is responsible for up to 78 percent of OA in the ankle.4 Furthermore, an estimated six million ankle fractures occur annually with five to ten percent of those having delayed union or nonunion.5 Surgical fixation alone results in inadequate treatment of some foot and ankle injuries. Ankle arthrodesis, commonly used in the setting of OA, has failure rates of up to 40 percent.6 Additionally, Achilles tendon re-rupture rates after operative treatment is as high as seven percent.7 Traumatic injuries, as well as patient medical and social factors, can predispose patients to poor healing, especially with soft tissue injuries. Over the past few decades, biologics have been implemented to aid in the healing process.8 Biologics, specifically orthobiologics, are biologically viable materials that can be used to improve healing in certain skeletal and soft tissue injuries.9

 

Kent Ellington, MD, FAAOS, Board Certified, American Academy of Orthopedic Surgeons and American Orthopaedic Foot and Ankle Society

  • Bachelor of Science, University of North Carolina Charlotte, Charlotte, NC
  • Doctor of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC
  • Residency in Orthopedic Surgery, Carolinas Medical Center, Charlotte, NC
  • Fellow, Institute for Foot & Ankle Reconstruction, Mercy Medical Center, Baltimore, MD

Dr. Ellington holds more than 20 years of research experience and is currently an Adjunct Assistant Professor of Biology at UNC Charlotte and an Associate Professor of Orthopaedics at Atrium Health’s Carolina Medical Center. He is active in teaching orthopedic residents and fellows and lectures regionally, nationally and internationally. Dr. Ellington has extensive experience in research and design of orthopedic implants, the development of novel technologies and advanced surgical techniques.

 

Mark Gould, MD

  • Board Certified, American Board of Orthopedic Surgery
  • Doctor of Medicine, Wright State University, Dayton, OH
  • Residency, Naval Medical Center of San Diego, San Diego, CA
  • Fellowship, University of Washington, Seattle, WA

Dr. Gould specializes in foot and ankle reconstructive surgery, sports-related injuries of the lower extremity and general orthopedics. Dr. Gould spent 24 years in the U.S. Navy. He combines broad experience with state-of-the-art non-operative and surgical treatment plans that optimize long-term functional outcome.

 

Jacob Wynes, DPM

  • Board Certified in Foot Surgery by the American Board of Foot and Ankle Surgery
  • Board Certified in Ankle Surgery by the American Board of Foot and Ankle Surgery
  • Doctor of Medicine, Temple University School of Podiatric Medicine, Temple University, Philadelphia, PA
  • Residency, Hospital of the University of Pennsylvania, Pennsylvania, PA
  • Fellowship in Foot and Ankle Deformity, Sinai Hospital of Baltimore, Baltimore, MD

Dr. Wynes currently manages foot and ankle care for children and adults at the University of Maryland Medical System. With his fellowship training in foot and ankle deformity correction, he is routinely called upon to provide advanced treatment options for congenital and progressive conditions including the treatment of advanced wounds. Dr. Wynes handles a vast array of issues, from the most basic bunion or hammertoe surgery to complex realignment and tendon transfers using cryopreserved amniotic membrane and umbilical cord allograft, ankle arthroscopy and metatarsal lengthening.

Albert Dunn, DO

  • Board Certified, Orthopedic Sports Medicine and Orthopedic Surgery
  • Doctor of Medicine, Lake Erie College of Osteopathic Medicine, Erie, PA
  • Residency, South Pointe Hospital, Warrensville Heights, OH
  • Fellowship in Sports Medicine/Orthopedics, Orthopaedic Foundation, Stamford, CT

Dr. Dunn is an orthopedic surgeon with subspecialty training in sports medicine. He graduated Magna Cum Laude from Gannon University in Erie, Pennsylvania majoring in biology and achieving membership in Beta-Beta-Beta, the national biological honor society. Dr. Dunn completed a one-year orthopaedic sports medicine fellowship with the world-renowned Orthopaedic Foundation in Stamford, CT, and New York City. During this intensive one-year subspecialty training, Dr. Dunn cared for high school, collegiate, Olympic and professional athletes while having the opportunity to learn from some of the world’s foremost authorities on shoulder, hip, knee, and adolescent sports surgery. Academically, Dr. Dunn has contributed multiple publications in peer-reviewed journals and lectured in various conference settings. His academic areas of interest include the shoulder, hip, and knee.

TissueTech maintains a Manufacturing Operations Department to support the Research and Development (R&D) laboratory’s technology transfer efforts and the production of Investigational New Drug Human Cell and Tissue Products. These manufacturing facilities include manufacturing clean rooms to facilitate successful media fills in accordance with the FDA 351 Regulatory Framework.

Today, manufacturing operations contribute to TissueTech’s success in establishing potency assays by ensuring the highest level of compliance with Current Good Manufacturing Practices (cGMPs) and by adhering to all additional regulatory requirements that are required for Independent Investigational New Drug and Biologic License Application submissions under the jurisdiction of Krista Roberts, Vice President of Operations at TissueTech.

Krista is available to speak on best practices, standards, and regulations as put forth in Current Good Tissue Practice requirements, Current Good Manufacturing Practice requirements, the FDA 21 Code of Federal Regulations Part 1271, and the American Association of Tissue Bank (AATB) Standards.

 

Krista Roberts, Vice President of Manufacturing Operations, TissueTech, Inc.

  • Bachelor of Science in Chemical Engineering from Louisiana Tech University
  • Master of Business Administration from the University of Arkansas at Little Rock

Krista Roberts maintains over 20 years of experience in strategic leadership of manufacturing operations in Lean-based Operational Excellence business systems. She has an extensive understanding of pharmaceutical manufacturing cGMPs and the ability to interact effectively with the FDA to improve quality systems through corrective and preventive actions and root cause analysis. Her experience includes aseptic processing, high volume filling operations and specialty device operations in addition to tissue processing. She has led the TissueTech transition from 361 Tissue Compliance to 351 Biologics compliance in manufacturing.

TissueTech maintains a Department of Health Policy and Government Affairs to oversee legal, regulatory, and legislative issues relative to healthcare delivery. This includes managing reimbursement and coverage issues conducting strategic work based upon reimbursement trends, coding and payment analysis, insurance authorization analysis, coverage analysis, and the development of relationships with regional and national payers. Additional duties include liaising with members of the Department of Health & Human Services, government agencies tasked with making healthcare decisions, specialty coalitions, and managed care organizations. These activities are all headed up by Tim Hunter, Vice President of Reimbursement and Government Affairs. Tim is available to speak on the advancement of health and health systems and shaping public policy to address today’s ongoing public health concerns.

 

Tim Hunter, Vice President of Reimbursement and Government Affairs, TissueTech, Inc.

  • Bachelor of Arts, Political Science and History, Syracuse University, Syracuse, NY
  • Master of Public Administration, Health Services Management and Policy, Syracuse University, Syracuse, NY

Tim holds more than 20 years of biotechnology industry experience in both reimbursement and government affairs with a strong background in health economics, payor education and coverage conversion, case-by-case denial appeals, longitudinal health economic analyses, facility value analyses, current and predictive payment models, and specialty society coalition building.

TissueTech has played a pivotal role in advancing ocular surface reconstruction with the introduction of a cryopreserved amniotic membrane ophthalmic graft in 1997. A second cryopreserved amniotic membrane ophthalmic graft was launched in 2003 followed by the 2010 launch of the Company’s first cryopreserved umbilical cord allograft. Today, TissueTech continues to pioneer in ocular surface research in collaboration with the FDA with research underway to support the commercialization of an amniotic membrane graft proposed for the treatment of neurotrophic keratitis, inflammation associated with moderate to severe dry eye disease, corneal ulcers, persistent corneal epithelial defect, and corneal epithelial keratitis. Dr. Desai is available to speak on clinical applications for the treatment of ocular surface disease and disorders using cryopreserved amniotic membrane and umbilical cord.

 

Neel Desai, MD

  • Board Certified, American Board of Ophthalmology
  • Bachelor of Science, University of Maryland, Baltimore, MD
  • Doctor of Medicine, Pennsylvania State University College of Medicine, Hershey, PA
  • Residency, Ophthalmology, Storm Eye Institute, Medical University of South Carolina, Charleston, SC
  • Fellow, Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, MD

Dr. Desai is an internationally recognized key opinion leader in ocular surface reconstruction with more than 25 years of experience in ophthalmologic medicine. He is acknowledged by his peers as being one of only a handful of ophthalmic surgeons able to perform advanced corneal transplants and other complex cataract, corneal and refractive procedures using human birth tissue allographs. Dr. Desai is available to speak on ocular surface disease and disorders, corneal wounds and ulcers, ocular surface reconstruction, and the clinical use of cryopreserved amniotic membrane and umbilical cord.

As a leading biotechnology company in ophthalmology, orthopedics, wound care, and pain management, TissueTech and its subsidiaries Bio-Tissue, Inc. and Amniox Medical, Inc. maintain a strong product development infrastructure through its Research and Development (R&D) Department. Capabilities include laboratory management and execution, e.g., supply inventory, equipment/environment selection, qualification, maintenance and monitoring, and research execution. All R&D operations are designed to ensure smooth life cycle management of product development and technology transfer in close collaboration with its Manufacturing Operations Department and in  collaboration with professional organizations and regulatory bodies including the American Academy of Ophthalmology and the American Medical Association, the Food and Drug Administration, the National Institutes of Health, the United States Department of Defense, and the Centers for Medicare and Medicaid Services.

 

Scheffer C.G. Tseng, MD, PhD, Chief Technology Officer and Co-Founder, Board Member, TissueTech, Inc.

  • Board Certification by American Board of Ophthalmology
  • Bachelor of Science, National Taiwan University, Taiwan
  • Medical Degree, Medical School, National Taiwan University, Taiwan
  • Doctorate in Experimental Pathology, University of California, San Francisco, CA
  • Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, Miami, Florida; Professor (Tenured), Charlotte Breyer Rodgers Chair in Ophthalmology; 1998-2001
  • Inaugural President, International Ocular Surface Society, 2001-2004
  • American Academy of Ophthalmology Senior Achievement Award 2004, Secretariat Award 2005, and Life Achievement Honor Award 2016
  • 2017 ARVO Gold Fellow, Association for Research in Vision and Ophthalmology, Inc.

Dr. Tseng is a world-renowned surgeon in ocular surface reconstruction. His research has been continuously supported by the National Institutes of Health National Eye Institute for more than 34 years. Dr. Tseng pioneered limbal stem cell transplantation and developed and commercialized the cryopreservation process known as CryoTek® to preserve the natural therapeutic properties of amniotic membrane.

Regenerative medicine covers a range of treatments intended to repair or replace damaged cells, tissues, or organs. It is an interdisciplinary field that applies engineering and life science principles to promote regeneration and can heal or replace tissues and organs damaged by age, disease, or trauma, as well as to normalize congenital defects. Regenerative medicine goes beyond disease management to search for and discover therapies that support the body in repairing and restoring itself to a state of well-being by prompting the body to enact a self-healing response. TissueTech co-founder Scheffer C.G. Tseng, MD, PhD has built the company into an evidence-based leader in the provision of human birth tissue products and pioneer in regenerative medicine. With more than 30 years of experience, Dr. Tseng is available to speak on regenerative medicine to restore structure and function of damaged tissues and organs. His research focus for the past 30 years has been to identify the active biological components of human birth  tissues, to develop alternative products to deliver their therapeutic properties, and to expand their clinical applications.

 

Scheffer C.G. Tseng, MD, PhD, Chief Technology Officer and Co-Founder, Board Member, TissueTech, Inc.

  • Board Certification by American Board of Ophthalmology
  • Bachelor of Science, National Taiwan University, Taiwan
  • Medical Degree, Medical School, National Taiwan University, Taiwan
  • Doctorate in Experimental Pathology, University of California, San Francisco, CA
  • Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, Miami, Florida; Professor (Tenured), Charlotte Breyer Rodgers Chair in Ophthalmology; 1998-2001
  • Inaugural President, International Ocular Surface Society, 2001-2004
  • American Academy of Ophthalmology Senior Achievement Award 2004, Secretariat Award 2005, and Life Achievement Honor Award 2016
  • 2017 ARVO Gold Fellow, Association for Research in Vision and Ophthalmology, Inc.

Dr. Tseng is a world-renowned surgeon in ocular surface reconstruction. His research has been continuously supported by the National Institutes of Health National Eye Institute for more than 34 years. Dr. Tseng pioneered limbal stem cell transplantation and developed and commercialized the cryopreservation process known as CryoTek® to preserve the natural therapeutic properties of amniotic membrane.

Chief Technology Officer and co-founder of TissueTech, Scheffer C. G. Tseng, MD, PhD has received grant support from the National Institutes of Health and the National Eye Institute since 1985. Basic and clinical research conducted under his oversight is related to the improvement of the diagnosis and treatment of ocular surface diseases. Examples of his translational research include coining the term and establishment of the diagnosis of limbal stem cell deficiency, pioneering autologous and allogeneic limbal stem cell transplantation, and amniotic membrane transplantation to restore sight in patients with corneal blindness caused by limbal stem cell deficiency.

From 2002 to 2014, scientists at TissueTech focused on searching for the molecular mechanism of amniotic membrane and umbilical cord human birth tissue to deliver anti-inflammatory and anti-scarring actions to promote wound healing. This included the identification and characterization of heavy chain-hyaluronic acid-pentraxin 3 (HC-HA/PTX3) as a unique extracellular matrix responsible for the amniotic membrane’s therapeutic actions. Today, TissueTech, Inc. and its subsidiaries Amniox Medical and Bio-Tissue, Inc. are pursuing rigorous Investigational New Drug clinical trials to support a Biologics Licensing Application. All TissueTech commercial products are regulated as either 361 Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) or 510(k) devices.

With more than 30 years of experience, Scheffer C.G. Tseng, MD, PhD, Chief Technology Officer, Board Member and Co-Founder of TissueTech, Inc. is available to speak on scientific research. His research focus for the past 30 years has been to identify the active biological components of human placental tissues, to develop alternative products to deliver their therapeutic properties, and to expand their clinical applications.

 

Scheffer C.G. Tseng, MD, PhD, Chief Technology Officer and Co-Founder, Board Member, TissueTech, Inc.

  • Board Certification by American Board of Ophthalmology
  • Bachelor of Science, National Taiwan University, Taiwan
  • Medical Degree, Medical School, National Taiwan University, Taiwan
  • Doctorate in Experimental Pathology, University of California, San Francisco, CA
  • Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, Miami, Florida; Professor (Tenured), Charlotte Breyer Rodgers Chair in Ophthalmology; 1998-2001
  • Inaugural President, International Ocular Surface Society, 2001-2004
  • American Academy of Ophthalmology Senior Achievement Award 2004, Secretariat Award 2005, and Life Achievement Honor Award 2016
  • 2017 ARVO Gold Fellow, Association for Research in Vision and Ophthalmology, Inc.

Dr. Tseng is the co-founder of TissueTech and a world-renowned surgeon in ocular surface reconstruction. His research has been continuously supported by the National Institutes of Health National Eye Institute for more than 34 years; he is a widely published physician scientist with more than 360 peer-reviewed clinical and scientific papers. Dr. Tseng pioneered limbal stem cell transplantation and developed and commercialized the CryoTek process to preserve the natural therapeutic properties of amniotic membrane. His research focus for the past 30 years has been to identify the active biological components of human placental tissues, to develop alternative products to deliver their therapeutic properties, and to expand their clinical applications.

Sports medicine is an area of medical practice concerned with the treatment of injuries resulting from athletic activities. Regenerative medicine offers sports medicine patients new options for nonsurgical treatment of common injuries without chronic pain or a permanent injury. Today, the field of regenerative medicine offers new and promising treatment options – two of which are cryopreserved amniotic membrane and cryopreserved umbilical cord derived from human birth tissue. Some of the most common orthopedic sport injuries include bone fractures, tear in the muscle or tendons, joint dislocations or injury to cartilage surrounding the joints. Over the last few years, the field of regenerative medicine has revolutionized the treatment of sports-related bone and joint injuries in the form of amniotic membrane allograft injections. Clinical experience is building a strong foundation of case-evidence for allograft injections to treat sports-related injuries including Achilles tendinosis, tibialis and peroneal tendinopathies, plantar fasciitis and other connective tissue bone and joint disorders.

 

Deryk Jones, MD

  • Board Certified, American Board of Orthopaedic Surgery with a Certification of Added Qualification in Sports Medicine
  • Doctor of Medicine, Stanford University School of Medicine, Stanford, CA
  • Residency, Harvard Combined Orthopaedics Residency Program, Boston, MA
  • Fellowship, University of Pittsburgh School of Medicine, Pittsburgh, PA

On completion of training, Dr. Jones joined the faculty of the Department of Orthopaedic Surgery at Tulane University School of Medicine where he holds an appointment as Clinical Assistant Professor at Tulane University. Dr. Jones began research while at Tulane University in basic scientific research on cartilage metabolism and regeneration, bone-tendon healing, periosteum cell characterization as well as softball and baseball throwing mechanics. Currently, his research focuses on examining clinical outcomes in both operative and nonoperative treatments of sports medicine related injuries and reconstructive techniques using cryopreserved amniotic membrane and umbilical cord human birth tissue allografts.

Trauma surgery is the branch of surgical medicine that deals with treating injuries caused by an impact and require immediate medical attention. Two prevalent orthopedic trauma procedures are the treatment of open fractures and tendon repair. Open fractures typically cause major soft tissue impact due to broken skin and require considerable wound care. The use of cryopreserved umbilical cord as an allograft has been found to be beneficial in helping to expedite wound healing, restore range of motion, and facilitate rapid rehabilitation for the patient. It is used as an adjunct in surgical procedures to repair and reconstruct torn or split tendons has shown to aid in managing adhesions and scar formation which can lead to compromised range of motion. Dr. Stewart has used cryopreserved amniotic membrane and umbilical cord in the successful treatment of more than 300 traumatic injury patients. He is available to speak on the treatment of complex traumatic injuries including acetabular fractures, intra-articular fractures, joint fractures, multi-extremity injuries, and pelvic fractures.

 

Christopher Stewart, MD

  • Board Certification, Orthopedic Surgery
  • Bachelor of Science, Microbiology and Cell Science, University of Florida, Gainesville, FL
  • Medical Degree, Ross University School of Medicine, Dominica West Indies
  • Residency Louisiana State University Health Sciences Center, Shreveport, LA
  • Fellow, Orthopedic Traumatology at the University of Tennessee College of Medicine, Chattanooga, TN

Dr. Stewart is a recognized key opinion leader and holds nearly 20 years of experience as an orthopedic surgeon specializing in the treatment of traumatic injuries. A specialist in orthopedic trauma, Dr. Stewart’s areas of expertise include pelvis and acetabular fractures, complex intra-articular (joint) fractures, multi-extremity injuries, and caring for multi-injured patients.

Reference:

1 Lipsky BA, Peters EJ, Senneville E, Berendt AR, Embil JM, Lavery LA, et al. Expert opinion on the management of infections in the diabetic foot. Diabetes Metab Res Rev 2012; 28: 163–78.

2 Shibuya N, Davis ML, Jupiter DC. Epidemiology of foot and ankle fractures in the United States: an analysis of the National Trauma Data Bank (2007 to 2011) J Foot Ankle Surg. 2014;53(5):606–608. doi: 10.1053/j.jfas.2014.03.011. [PubMed] [CrossRef] [Google Scholar]

3 Waterman BR, Owens BD, Davey S, Zacchilli MA, Belmont PJ., Jr The epidemiology of ankle sprains in the United States. J Bone Joint Surg Am. 2010;92(13):2279–2284. doi: 10.2106/JBJS.I.01537. [PubMed] [CrossRef] [Google Scholar]

4 Thomas AC, Hubbard-Turner T, Wikstrom EA, Palmieri-Smith RM. Epidemiology of posttraumatic osteoarthritis. J Athl Train. 2017;52(6):491–496. doi: 10.4085/1062-6050-51.5.08. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

5 American Academy of Orthopaedic Surgeons American Academy of Orthopaedic S. Musculoskeletal conditions in the United States. Second edition. ed. Praemer A, Furner S, Rice DP, editors: Park Ridge, IL: American Academy of Orthopaedic Surgeons; 1999.

6 Frey C, Halikus NM, Vu-Rose T, Ebramzadeh E. A review of ankle arthrodesis: predisposing factors to nonunion. Foot & Ankle International. 1994;15(11):581–584. doi: 10.1177/107110079401501102. [PubMed] [CrossRef] [Google Scholar]

7 Reito A, Logren H-L, Ahonen K, Nurmi H, Paloneva J. Risk factors for failed nonoperative treatment and rerupture in acute Achilles tendon rupture. Foot & Ankle International. 2018. [PubMed]

8 Sochacki KR, Jack RA, Cosculluela PE. Osteochondral lesions of the talus: osteochondral allograft transplantation. Operative Techniques in Sports Medicine. 2017;25(2):120–128. doi: 10.1053/j.otsm.2017.03.008. [CrossRef] [Google Scholar]

9 Wee J, Thevendran G. The role of orthobiologics in foot and ankle surgery: allogenic bone grafts and bone graft substitutes. EFORT Open Rev. 2017;2(6):272–280. doi: 10.1302/2058-5241.2.160044. [PMC free article] [PubMed] [CrossRef] [Google Scholar]